Bellini Chiara, Nori Cucchiari Jacopo, Di Naro Federica, De Benedetto Diego, Bicchierai Giulia, Franconeri Andrea, Renda Irene, Bianchi Simonetta, Susini Tommaso
Diagnostic Senology Unit, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence, Italy.
Breast Unit, Gynecology Section, Department of Health Sciences, University of Florence, 50121 Florence, Italy.
Cancers (Basel). 2023 Jul 6;15(13):3521. doi: 10.3390/cancers15133521.
Breast lesions of uncertain malignant potential (B3) are frequently diagnosed in the era of breast cancer (BC) screening and their management is controversial. They are generally removed surgically, but some international organizations and guidelines for breast research suggest follow-up care alone or, more recently, propose vacuum-assisted excision (VAE). The risk of upgrade to BC is known, but very little data exist on its role as risk factor for future BC development. We analyzed 966 B3 lesions diagnosed at our institution, 731 of which had long-term follow-up available. Surgical removal was performed in 91%, VAE in 3.8%, and follow-up in 5.2% of cases. The B3 lesions included flat epithelial atypia (FEA), atypical ductal hyperplasia (ADH), lobular intraepithelial neoplasia (LIN), atypical papillary lesions (PLs), radial scars (RSs), and others. Overall, immediate upgrade to BC (invasive or in situ) was 22.7%. After long-term follow-up, 9.2% of the patients were diagnosed with BC in the same or contralateral breast. The highest risk was associated with ADH diagnosis, with 39.8% of patients upgraded and 13.6% with a future BC diagnosis ( < 0.0001). These data support the idea that B3 lesions should be removed and provide evidence to suggest annual screening mammography for women after a B3 diagnosis because their BC risk is considerably increased.
在乳腺癌筛查时代,经常会诊断出恶性潜能不确定的乳腺病变(B3),其处理方式存在争议。这些病变通常通过手术切除,但一些国际乳腺研究组织和指南建议仅进行随访观察,或者最近提出采用真空辅助切除(VAE)。升级为乳腺癌的风险是已知的,但关于其作为未来乳腺癌发生风险因素的作用的数据却非常少。我们分析了在我们机构诊断出的966例B3病变,其中731例有长期随访资料。91%的病例进行了手术切除,3.8%进行了VAE,5.2%进行了随访观察。B3病变包括扁平上皮异型增生(FEA)、非典型导管增生(ADH)、小叶原位癌(LIN)、非典型乳头状病变(PLs)、放射状瘢痕(RSs)等。总体而言,立即升级为乳腺癌(浸润性或原位癌)的比例为22.7%。经过长期随访,9.2%的患者在同侧或对侧乳腺被诊断出患有乳腺癌。ADH诊断的风险最高,39.8%的患者升级,13.6%的患者未来被诊断出患有乳腺癌(P<0.0001)。这些数据支持应切除B3病变的观点,并为B3诊断后的女性建议每年进行乳腺钼靶筛查提供了证据,因为她们患乳腺癌的风险显著增加。